All posts by: Michael Zand

About Michael Zand

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs – Business Wire (press release)

Continue reading

2017-10-04 NEWS

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
Business Wire (press release)
“With immunotherapies dominating the treatment landscape, we continually find that our technology can help our partners, such as Pelican, advance candidates for unmet medical needs including certain cancers,” said Yemi Onakunle, PhD, MBA, Selexis vice …

Continue reading

2017-10-04 NEWS

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
Business Wire (press release)
“With immunotherapies dominating the treatment landscape, we continually find that our technology can help our partners, such as Pelican, advance candidates for unmet medical needs including certain cancers,” said Yemi Onakunle, PhD, MBA, Selexis vice …

Continue reading

2017-10-04 NEWS

News-Medical.net

Patented invention has potential to induce and regulate stem cell differentiation
News-Medical.net
An invention by Florida Institute of Technology’s Shengyuan Yang was found to naturally narrow the spreading of stem cells and has the potential to induce and regulate their differentiation. Using Yang’s patented and patent-pending technology, stem

Continue reading

2017-10-04 NEWS

News-Medical.net

Patented invention has potential to induce and regulate stem cell differentiation
News-Medical.net
An invention by Florida Institute of Technology’s Shengyuan Yang was found to naturally narrow the spreading of stem cells and has the potential to induce and regulate their differentiation. Using Yang’s patented and patent-pending technology, stem

Continue reading

2017-10-04 NEWS

Novartis’s Kymriah becomes first gene therapy to get FDA approval
The Cancer Letter Publications
The agent, sponsored by Novartis Pharmaceuticals Corp., was approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia. On July 12, the FDA Oncologic Drugs Advisory Committee unanimously recommended that the agent …

Continue reading

2017-10-04 NEWS

Novartis’s Kymriah becomes first gene therapy to get FDA approval
The Cancer Letter Publications
The agent, sponsored by Novartis Pharmaceuticals Corp., was approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia. On July 12, the FDA Oncologic Drugs Advisory Committee unanimously recommended that the agent …